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 Chronic Obstructive Pulmonary 
Disease:  Longitudinal Hyperpolarized 
 3 He MR Imaging 1 
 Miranda  Kirby ,  BSc 
 Lindsay  Mathew ,  BMSc 
 Andrew  Wheatley ,  BSc 
 Giles E.  Santyr ,  PhD 
 David G.  McCormack ,  MD 
 Grace  Parraga ,  PhD 
 Purpose: To quantitatively evaluate a small pilot group of ex-smokers 
with chronic obstructive pulmonary disease (COPD) and 
healthy volunteers during approximately 2 years by using 
hyperpolarized helium 3 ( 3 He) magnetic resonance (MR) 
imaging.
 Materials and 
Methods: 
All subjects provided written informed consent to the study 
protocol, which was approved by the local research ethics 
board and Health Canada and was compliant with the Per-
sonal Information Protection and Electronic Documents 
Act and HIPAA. Hyperpolarized  3 He MR imaging, hydro-
gen 1 MR imaging, spirometry, and plethysmography were 
performed in 15 ex-smokers with COPD and fi ve healthy 
volunteers (with the same mean age and age range) at 
baseline and 26 months  6 2 (standard deviation) later. 
Apparent diffusion coeffi cients (ADCs) derived from  3 He 
MR imaging were calculated from diffusion-weighted  3 He 
MR images, and  3 He ventilation defect volume (VDV) and 
ventilation defect percentage (VDP) were generated after 
manual segmentation of  3 He MR spin-density images.
 Results: For subjects with COPD, signifi cant increases in  3 He MR 
imaging–derived VDV ( P = .03), VDP ( P = .006), and 
ADC ( P = .02) were detected, whereas there was no sig-
nifi cant change in forced expiratory volume in 1 second 
(FEV 1 ) ( P = .97). For healthy never-smokers, there was 
no signifi cant change in imaging or pulmonary function 
measurements at follow-up. There was a signifi cant cor-
relation between changes in FEV 1 and changes in VDV 
( r =  2 0.70,  P = .02) and VDP ( r =  2 0.70,  P = .03).
 Conclusion: For this small pilot group of ex-smokers with COPD,  3 He 
MR imaging–derived VDV, VDP, and ADC measurements 
worsened signifi cantly, but there was no signifi cant change 
in FEV 1 , suggesting increased sensitivity of hyperpolarized 
 3 He MR imaging for depicting COPD changes during short 
time periods.
 q RSNA, 2010
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 Materials and Methods 
 Subjects 
 Twenty subjects were enrolled from 
the general population of the local ter-
tiary health care center, as previously 
described ( 20 ). All subjects provided 
written informed consent to the study 
protocol, which was approved by the 
local research ethics board and Health 
Canada, and the study was compliant 
with the Personal Information Protec-
tion and Electronic Documents Act and 
the Health Insurance Portability and 
Accountability Act. Subjects with COPD 
were enrolled who were ex-smokers be-
tween the ages of 50–70 years and who 
had a clinical diagnosis of COPD. Those 
enrolled subjects with COPD were cate-
gorized according to the Global Initiative 
for Chronic Obstructive Lung Disease 
criteria ( 4 ) and had a smoking history 
of at least 10 pack-years and had fewer 
than three COPD exacerbations within 
the past 12 months. Exacerbations dur-
ing the follow-up period were defi ned 
as hospitalization for COPD or as the 
patient’s fi rst-time need for antibiotic 
or prednisone therapy, and these were 
reported from hospital records ( 36 ) 
and subject charts and were addition-
ally verifi ed with a telephone interview 
with the subject after follow-up imaging 
was completed. Subjects with COPD 
were excluded during a screening visit 
( 12–14 ) and depicts signifi cant COPD 
changes during relatively short periods 
of time ( 15 ). 
 Hyperpolarized helium 3 ( 3 He) 
magnetic resonance (MR) imaging has 
recently emerged as another research 
method for the evaluation of COPD 
( 16–20 ). In particular, previous work 
showed that the apparent diffusion 
coeffi cient (ADC) derived from  3 He 
MR imaging ( 16,21–23 ) was a sensi-
tive measurement of emphysematous 
destruction ( 19,23,24 ) and airspace 
size ( 16,17,25,26 ) and correlated with 
pulmonary function (FEV 1 and diffus-
ing capacity of lung for carbon mon-
oxide) ( 27 ), as well as histologic mea-
surements of lung surface area ( 28 ). 
Importantly,  3 He MR imaging–derived 
ADC is also age dependent ( 29 ) and 
refl ects differences in patient anatomic 
position ( 30 ), disease severity ( 31 ), and 
smoking history ( 32 ). Quantitative fo-
cal  3 He MR imaging–derived ventilation 
defects have also been shown in COPD 
( 24,32–34 ), and these refl ect differ-
ences in subject age ( 35 ) and disease 
status ( 20 ). To better understand the 
potential for hyperpolarized  3 He MR 
imaging to provide quantitative longitu-
dinal COPD end points, we designed a 
pilot longitudinal  3 He MR imaging study 
of COPD. The purpose of this study 
was to quantitatively evaluate a small 
pilot group of ex-smokers with COPD 
and healthy volunteers over the course 
of approximately 2 years by using hy-
perpolarized  3 He MR imaging. 
 Chronic obstructive pulmonary dis-ease (COPD) is a leading cause of morbidity and mortality and af-
fects at least 600 million people world-
wide ( 1 ). It is the world’s fourth leading 
cause of death and the most common 
chronic, terminal respiratory disease 
( 2 ). Because of the heterogeneous na-
ture of COPD, studies of its natural his-
tory and progression are complex, typi-
cally requiring large-study sample sizes 
and long durations to obtain relevant 
longitudinal end points. Accordingly, 
much of our current understanding of 
the natural history of COPD arises from 
the landmark study of Fletcher and 
Peto ( 3 ) and is based on cross-sectional 
spirometric measurements of forced 
expiratory volume in 1 second (FEV 1 ). 
The current functional defi nition of 
COPD ( 4 ) is also based on FEV 1 , and 
change in FEV 1 over the course of time 
is still the most widely accepted mea-
sure of COPD progression. However, a 
number of limitations of spirometry for 
the diagnosis, classifi cation, and longi-
tudinal monitoring of COPD are moti-
vating the development of new COPD 
measurements ( 5 ), including those de-
rived from noninvasive imaging ( 6,7 ). 
For example, thin-section multidetec-
tor computed tomography (CT) ( 8–11 ) 
has been used to identify phenotypes 
of both emphysema and airway disease 
 Implication for Patient Care 
 In a small group of ex-smokers  n
with COPD, hyperpolarized  3 He 
MR imaging depicted signifi cant 
changes in apparent diffusion 
coeffi cient and ventilation mea-
surements, whereas there was no 
signifi cant change in FEV 1 ; this 
fi nding suggests that regional  3 He 
MR imaging measurements pro-
vide adequate sensitivity for 
detecting COPD changes during 
relatively short time periods, 
before signifi cant changes in 
FEV 1 can be detected. 
 Advances in Knowledge 
 In a small group of ex-smokers  n
with chronic obstructive pulmo-
nary disease (COPD), hyperpo-
larized  3 He MR imaging measure-
ments showed signifi cant 
progression after 26 months, 
whereas forced expiratory 
volume in 1 second (FEV 1 ) did 
not signifi cantly change. 
 There was a signifi cant inverse  n
correlation between changes in 
 3 He MR imaging–derived ventila-
tion defect volume measurements 
and FEV 1 . 
 Hyperpolarized   n 3 He MR imaging 
is a sensitive tool for the quanti-
tative longitudinal evaluation of 
COPD. 
 Published online 
 10.1148/radiol.10091937 
Radiology 2010; 256:280–289
 Abbreviations: 
 ADC = apparent diffusion coeffi cient 
 COPD = chronic obstructive pulmonary disease 
 FEV 1 = forced expiratory volume in 1 second 
 VDV = ventilation defect volume 
 VDP = ventilation defect percentage 
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 Image Analysis 
 The signal-to-noise ratio for all images 
acquired was determined by calculat-
ing the mean pixel value within a 10  3 
10-voxel region of interest for four rep-
resentative regions of interest within 
the lung parenchyma and dividing by 
the standard deviation of the mean pixel 
values for noise inside a region of inter-
est of the same size at the corners of the 
image where there was no lung struc-
ture. Signal-to-noise ratio was deter-
mined for each section and then was av-
eraged to obtain a single signal-to-noise 
ratio for each subject and time point. 
Images were analyzed in a controlled 
image visualization environment with 
room lighting levels equivalently estab-
lished for all image analysis sessions. 
 ADC maps were processed by us-
ing in-house software programmed in 
the interactive data language Virtual 
Machine platform (Research Systems, 
Denver, Colo) as previously described 
( 33 ) with a  b value of 1.6 sec/cm 2 . Spin-
density images were examined for analysis 
of ventilation defects in all coronal sec-
tions by two expert observers (M.K. and 
L.M.) blinded to subject identity, disease 
status, and time point, as well as the other 
observer’s measurements. As previously 
described ( 39 ), a ventilation defect was 
identifi ed by each observer indepen-
dently as any lung region of diminished 
signal intensity but not those areas of 
signal loss associated with the pulmo-
nary vascular structures, heart, hilum, 
and mediastinum. Images were reviewed 
such that  3 He and  1 H images were visible 
on a digital workstation monitor system 
(consisting of identical 19-inch fl at panel 
monitors). Manual segmentation of ven-
tilation defects was performed by using 
custom-designed image visualization 
software that also provided a method for 
two-dimensional rigid single-point image 
registration ( 1 H and  3 He sections) based 
on the carina, which facilitated the man-
ual segmentation of ventilation defects 
in all sections. Ventilation defect volume 
(VDV) and thoracic cavity volume were 
recorded following manual segmenta-
tion of  3 He and  1 H images, respectively, 
and were used to calculate ventilation 
defect percentage (VDP) ( 16,25,26,40 ). 
VDV was derived from the manually 
Wis) with broadband imaging capabil-
ity, as previously described ( 33 ). All 
 3 He MR imaging was performed with a 
whole-body gradient set with a maxi-
mum gradient amplitude of 1.94 G/cm 
and a single-channel, rigid elliptical 
transmit-receive chest coil (RAPID Bio-
medical, Würzburg, Germany). The ba-
sis frequency of the coil was 97.3 MHz, 
and excitation power was 3.2 kW by 
using a radiofrequency power amplifi er 
(AMT 3T90; GE Healthcare, Milwaukee, 
Wis). 
 Coronal two-dimensional multiple-
section hydrogen 1 ( 1 H) images were 
acquired prior to  3 He MR imaging, with 
subjects imaged during 1-L breath hold 
of the  4 He-N 2 mixture from a starting 
point of functional residual capacity by 
using a whole-body radiofrequency coil 
and a proton fast spoiled-gradient-echo 
sequence (16-second total data acquisi-
tion; repetition time msec/echo time 
msec, 4.7/1.2; fl ip angle, 30°; fi eld of 
view, 40  3 40 cm; matrix, 256  3 256; 14 
sections; 15-mm section thickness; 0-cm 
intersection gap). For diffusion-weighted 
imaging, coronal multisection images 
were obtained by using a fast gradient-
echo method with centric k-space sam-
pling. Two interleaved images (14-second 
total data acquisition; 7.6/3.7; fl ip angle, 
8°; fi eld of view, 40  3 40 cm; matrix, 
128  3 128; seven sections; 30-mm sec-
tion thickness), with and without addi-
tional diffusion sensitization (maximum 
gradient amplitude = 1.94 G/cm, rise and 
fall time = 0.5 msec, gradient duration = 
0.46 msec, diffusion time = 1.46 msec, 
 b value = 1.6 sec/cm 2 ), were acquired. For 
ventilation, or spin-density, imaging, cor-
onal multisection images were obtained 
by using the same  3 He coil (14-second 
total data acquisition; 4.3/1.4; fl ip angle, 
7°; bandwidth, 31.25 kHz; fi eld of view, 
40  3 40 cm; matrix, 128  3 128; 14 sec-
tions; 15-mm section thickness; 0-cm 
intersection gap) and multisection two-
dimensional simultaneous acquisition 
of a ventilation image (no T1-weighted 
sensitization) and a T1-weighted im-
age. Only images without T1-weighting 
were used for ventilation analysis in this 
study. All imaging was completed within 
approximately 7–10 minutes of subjects 
fi rst lying in the imager. 
if FEV 1 was greater than 3% after ad-
ministration of salbutamol. Healthy vol-
unteers were enrolled (same age range 
as the subjects with COPD) who had 
a smoking history of less than 1 pack-
year with no smoking in the previous 25 
years and no history of previous chronic 
or current respiratory disease. All tests 
and imaging were performed at base-
line and at 26 months  6 2 (standard 
deviation). 
 Pulmonary Function Tests 
 Spirometry was performed by using a 
spirometer (ndd EasyOne; Medizin-
technik, Zurich, Switzerland) to report 
FEV 1 and forced vital capacity with a 
minimum of three acceptable spirom-
etry maneuvers; the best FEV 1 and 
forced vital capacity were selected for 
analysis according to American Tho-
racic Society guidelines ( 37 ). Whole-
body plethysmography was performed 
by using a stand-alone body plethys-
mograph (Elite Series; MedGraphics, 
St Paul, Minn) for the measurement of 
total lung capacity, inspiratory capacity, 
residual volume, and functional residual 
capacity. 
 MR Imaging 
 Subjects were screened for MR imag-
ing and coil compatibility (inner diam-
eter of elliptical coil = 50 cm) prior 
to imaging, and digital pulse oximetry 
was used to monitor arterial blood 
oxygenation levels during breath-hold 
MR imaging. A turnkey, spin-exchange 
polarizer system (HeliSpin; GE Health-
care, Durham, NC) was used to polar-
ize  3 He gas to 30%–40%, as previously 
described ( 38 ). Doses of hyperpolar-
ized  3 He gas (5 mL per kilogram of 
body weight) were administered in 
1-L plastic bags (Tedlar; Jensen Inert 
Products, Coral Springs, Fla) and were 
diluted with ultrahigh purity, medical-
grade nitrogen (Spectra Gases, Alpha, 
NJ). Polarization of the diluted dose 
was quantifi ed at a polarimetry station 
(GE Healthcare, Durham, NC) imme-
diately prior to  3 He gas administration 
to subject. 
 MR imaging was performed with a 
whole-body 3.0-T MR imaging system 
(Excite 12.0; GE Healthcare, Milwaukee, 
Radiology: Volume 256: Number 1—July 2010 n radiology.rsna.org 283
 THORACIC IMAGING: Chronic Obstructive Pulmonary Disease at  3 He MR Imaging Kirby et al
were nonsmokers at baseline with a 
mean smoking history of 47 pack-years 
 6 22 (range, 11–85 pack-years) and 
mean years of not smoking at baseline 
of 11 years  6 10 (range, 10 weeks to 
34 years). Three subjects experienced 
a single COPD exacerbation during the 
follow-up period. 
 Table 2 shows mean and median 
whole-lung and center-section hyperpo-
larized  3 He MR imaging measurements 
for healthy never-smokers and subjects 
with COPD. The absolute change and 
annualized rates of change of FEV 1 and 
hyperpolarized  3 He MR imaging mea-
surements for subjects with COPD are 
provided in  Table 3 . For ADC, annual-
ized rate of change for ex-smokers with 
COPD was 0.01 cm 2 /sec and that for 
never-smokers was 0.002 cm 2 /sec. There 
was no signifi cant association between 
the changes in image signal-to-noise ra-
tio and the changes in ADC ( r =  2 0.51, 
 P = .12) and VDV ( r =  2 0.17,  P = .55). 
Interobserver reproducibility of  3 He MR 
imaging–derived VDV was previously 
evaluated for three observers, and this 
was the same as intraobserver variability 
(coeffi cient of variation = 10%, unpub-
lished results). For two observers, inter-
observer reproducibility was assessed for 
whole-lung VDV (interclass correlation co-
effi cient = 0.93, coeffi cient of variation = 
38%, and  r 2 = 0.84 [ P  , .0001]) and 
whole-lung VDP (interclass correlation 
coeffi cient = 0.91, coeffi cient of varia-
tion = 43%, and  r 2 = 0.81 [ P  , .0001]). 
and Spearman correlation coeffi cients 
(Prism, version 4.00). The Holm-
Bonferroni correction ( 41 ) was used for 
multiple paired  t tests and all correla-
tions. The Holm-Bonferroni–adjusted 
 P values were determined by ordering 
 P values from smallest to largest, with 
the smallest  P value multiplied by  k , 
where  k is the number of hypotheses 
to be tested. If the resulting modifi ed 
 P value was less than  a (type I error 
rate), the hypothesis was rejected. The 
next smallest  P value was then multi-
plied by  k  2 1, and the new modifi ed 
 P value was compared with  a . This 
process was repeated until the modi-
fi ed  P value could not be rejected. In all 
statistical analyses, results were consid-
ered signifi cant when the probability of 
making a type I error was less than 5% 
( P  , .05). A retrospective sample size 
( n ) calculation was performed to detect 
a signifi cant change ( d ) in FEV 1 with  a 
equal to .05 and power  b equal to .80 
and where SD is standard deviation; ac-
cordingly,  Z  a  was 1.96 and  Z  b  was 0.2, 
and  n was calculated according to the 
following equation ( 42 ): 
 
 2 2
2
2 SD
.
Z Z
n
 a b
d  
 Results 
 Demographic characteristics are provided 
in  Table 1 . All subjects with COPD 
segmented ventilation defect area for 
each section, and this was multiplied by 
the section thickness; VDV for all sec-
tions was summed to obtain whole-lung 
VDV. For the center section, which was 
the middle section acquired that clearly 
showed the carina and two main bron-
chi, VDV was also manually segmented 
and reported. In addition, whole-lung 
and center-section measurements were 
recorded for thoracic cavity volume for 
calculation of whole-lung and center-
section VDP, as well as for ADC. 
 Statistical Methods 
 For  3 He MR imaging ventilation mea-
surements, observer reproducibility 
was evaluated for two observers by us-
ing the interclass correlation coeffi -
cient, coeffi cient of variation, and lin-
ear regression ( r 2 ) by using software 
(SPSS, version 16.00; SPSS, Chicago, 
Ill). Comparison of baseline and follow-up 
means was performed by using a Wil-
coxon matched-pairs two-tailed  t test 
(SPSS, version 16.00). The relationship 
between changes in  3 He MR imaging 
measurements and changes in pulmo-
nary function measurements at follow-up 
was determined by using linear re-
gression and Spearman correlation 
coeffi cients by using software (Prism, 
version 4.00; GraphPad Software, San 
Diego, Calif). The relationship be-
tween the changes in  3 He MR imaging–
derived VDV and smoking history was 
determined by using linear regression 
 Table 1 
 Subject Demographic Characteristics in Ex-Smokers with COPD and Never-Smokers 
Parameter
Healthy Never-Smokers ( n = 5) Ex-Smokers with COPD ( n = 15)
Baseline Follow-up Baseline Follow-up
Age (y)    69  6 6 (58–74)    72  6 6 (61–76)    68  6 6 (59–75)    70  6 5 (61–77)
No. of men     2      2      8      8
Body mass index (kg/m 2 )    25  6 2 (24–29)    25  6 2 (23–28)    28  6 5 (19–38)    27  6 5 (18–37)
FEV 1 (L) 2.77  6 1.01 2.62  6 0.93 1.51  6 0.63 1.43  6 0.56
FEV 1 (percentage predicted)  110  6 23  107  6 23    53  6 15    52  6 15
FEV 1 /FVC ratio    77  6 4    78  6 15    45  6 14    49  6 16
Inspiratory capacity (%)  106  6 18 ...    88  6 23    82  6 22
Reserve volume (%)    95  6 15 ...  157  6 48  132  6 33
Functional residual capacity (%)  101  6 12 ...  145  6 65  131  6 33
Total lung capacity (%)  105  6 12 ...  109  6 17  105  6 10
Note.—Unless otherwise indicated, data are means  6 standard deviations, with ranges in parentheses.
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subjects with COPD at baseline and 
follow-up. 
 Table 4 shows Spearman correla-
tion coeffi cients for the relationship 
between the changes in FEV 1 (absolute 
and percentage predicted) and those in 
 3 He MR imaging–derived ADC, VDV, 
and VDP for subjects with COPD. As 
shown in  Figure 3 , the change in FEV 1 
(absolute) showed a signifi cant negative 
association with the change in center-
section VDV ( r =  2 0.70,  P = .02) and 
center-section VDP ( r =  2 0.70,  P = 
.03) but not with the change in ADC. 
Thoracic cavity volume was calculated 
for all subjects from  1 H MR imag-
ing of the thoracic cavity, and for all 
subjects, the change in thoracic cav-
ity volume was signifi cantly correlated 
with the change in total lung capacity 
measured by using plethysmography ( r = 
0.81,  P = .001).  Figure 4 shows the re-
lationships between smoking history 
of patients with COPD (pack-years 
smoking) and the changes in  3 He MR 
 Table 3 
 Annualized Change in Pulmonary Function and  3 He MR Imaging Measurements in 
Subjects with COPD at Follow-up 
Parameter Absolute Change Annualized Rate of Change  P Value * 
FEV 1 (percentage predicted)  2 1  2 0.4 .97 (.97)
Whole-lung ADC (cm 2 /sec) 0.02 0.01 .01 (.02)
Center-section ADC (cm 2 /sec) 0.03 0.01 .004 (.02)
Whole-lung VDV (L) 0.4 0.20 .007 (.03)
Center-section VDV (L) 0.05 0.03 .003 (.02)
Whole-lung VDP (%) 7 4 .0009 (.006)
Center-section VDP (%) 7 3 .01 (.03)
* Data are  P values determined with Wilcoxon matched-pairs two-tailed  t tests, with Holm-Bonferroni–adjusted  P values in 
parentheses.
Figure E1 (online) shows the relation-
ship between ventilation defect measure-
ments (whole-lung VDV [ r 2 = 0.84,  P  , 
.0001] and whole-lung VDP [ r 2 = 0.81, 
 P  , .0001]) for observer 1 and 2. The 
change at follow-up for observer 1 and 
2 were signifi cantly correlated for whole-
lung VDV ( r 2 = 0.51,  P = .0004) and 
whole-lung VDP ( r 2 = 0.39,  P = .007). 
The change in whole-lung VDV and 
whole-lung VDP for each observer and 
the mean for both observers is provided 
in Table E1 (online), and throughout the 
main body of the article, a single observ-
er’s results are described. Table E2 (on-
line) shows a subject listing of baseline 
and follow-up pulmonary function and 
 3 He MR imaging measurements. 
 Wilcoxon matched-pairs two-tailed 
 t tests indicated that all  3 He MR imaging 
measurements were signifi cantly differ-
ent at follow-up for subjects with COPD. 
There was no signifi cant change ob-
served in FEV 1 (percentage predicted) 
for subjects with COPD at follow-up. 
For healthy never-smokers, there was 
no detectable change in any pulmonary 
function or imaging measurement. The 
changes detected in the ex-smokers with 
COPD were signifi cantly different than 
the changes measured in the healthy vol-
unteers for whole-lung VDV ( P = .04) 
and whole-lung VDP ( P = .01) but were 
not signifi cantly different for whole-lung 
ADC ( P = .96) or FEV 1 ( P = .21). 
 Figure 1 shows ventilation images, 
ADC maps, and ADC histograms for two 
representative healthy never-smokers at 
baseline and follow-up.  Figure 2 shows 
ventilation images, ADC maps, and 
ADC histograms for two representative 
 Table 2 
 Helium 3 MR Imaging–derived ADC and Ventilation Defect Measurements at Baseline and Follow-up 
Parameter
Healthy Never-Smokers ( n = 5) Ex-Smokers with COPD ( n = 15)
Baseline Follow-up Baseline Follow-up 
Whole-lung ADC (cm 2 /sec) 0.27 (0.25) [0.02] 0.29 (0.29) [0.03] 0.43 (0.45) [0.08] 0.46 (0.46) [0.07]
Center-section ADC (cm 2 /sec) 0.28 (0.27) [0.02] 0.28 (0.30) [0.03] 0.44 (0.45) [0.09] 0.47 (0.46) [0.08]
Whole-lung VDV (L) 0.023 (0.006) [0.04] 0.020 (0.017) [0.02] 0.52 (0.24) [0.54] 0.92 (0.77) [0.93]
Center-section VDV (L) 0.003 (0.000) [0.005] 0.002 (0.001) [0.002] 0.056 (0.023) [0.053] 0.11 (0.11) [0.11]
Whole-lung VDP (%) 0.5 (0.2) [0.9] 0.5 (0.5) [0.4] 9 (6) [9] 16 (15) [14]
Center-section VDP (%) 0.6 (0.2) [0.9] 0.4 (0.2) [0.4] 9 (11) [13] 16 (16) [22]
Note.—Data are means, with medians in parentheses and standard deviations in brackets.
imaging–derived VDV and FEV 1 . There 
was no signifi cant correlation between 
pack-years smoking and the change in 
FEV 1 ( r = 0.05,  P = .83), and the re-
lationship between pack-years smoking 
and whole-lung VDV was moderate, but 
once corrected for multiple tests, this 
relationship was on the threshold of 
signifi cance (whole-lung VDV [ r = 0.52; 
 P = .02, uncorrected;  P = .06, Holm-
Bonferroni corrected]). 
 Discussion 
 Several observations were made in this 
small longitudinal pilot study. First, we 
observed that mean  3 He MR imaging–
derived ADC, VDV, and VDP signifi -
cantly increased during the 26-month 
follow-up period in 15 ex-smokers 
with COPD, whereas pulmonary func-
tion measurements did not signifi cantly 
change during the same time period. 
Because of the previously reported and 
pioneering epidemiologic fi ndings of 
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 Figure 1 
  
 Figure 1: Representative hyperpolarized  3 He MR data at baseline (top) and follow-up (bottom) in healthy never-smokers. Left:  A,  Ventilation 
image,  B, ADC map, and,  C, ADC histogram in 58-year-old man (subject 1001). Right:  A, Ventilation image,  B, ADC map, and,  C, ADC histogram 
in 73-year-old man (subject 1007). 
 Figure 2 
  
 Figure 2: Representative hyperpolarized  3 He MR data show VDV and ADC changes during follow-up in COPD. Left:  A, Ventilation image,  B, 
ADC map, and,  C, and ADC histogram in 75-year-old man with stage III COPD (subject 3004). Right:  A, Ventilation image,  B, ADC map, and,  C, 
ADC histogram in 61-year-old man with stage II COPD (subject 2009). Top = baseline, bottom = follow-up. 
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These preliminary longitudinal fi ndings 
suggest that regional disease mark-
ers derived at noninvasive imaging can 
be used in a small number of subjects 
with COPD during short time peri-
ods to quantitatively detect signifi cant 
changes. 
 We also showed that the change in 
 3 He MR imaging–derived VDV and VDP 
indicated a signifi cant inverse correla-
tion with the change in FEV 1 , whereas 
the change in ADC showed no such re-
lationship. This result suggests that  3 He 
MR imaging–derived ventilation defect 
measurements may be more predic-
tive of airfl ow limitation than  3 He MR 
imaging–derived ADC, which necessi-
tates further testing of this hypothesis. 
Although we observed statistically sig-
nifi cant improvements in FEV 1 of less 
than 20 mL in fi ve subjects with COPD, 
we did not observe a corresponding im-
provement in  3 He MR imaging–derived 
measurements during this time period. 
On the contrary, for these fi ve subjects, 
we observed a statistically signifi cant 
increase in  3 He MR imaging–derived 
ADC ( P = .02) and no change in ven-
tilation measurements. We believe this 
discordant fi nding highlights the sensi-
tivity of using both ventilation and ADC 
measurements in detecting disease 
changes in COPD. In a related fi nding, 
Ohara and colleagues ( 15 ) showed a 
signifi cant inverse correlation between 
annual changes in FEV 1 and CT mea-
surement of wall area percentage (a 
surrogate of airway wall thickness), 
and, similar to our results, there was 
no signifi cant relationship between the 
change in FEV 1 and emphysema (per-
centage of low attenuation areas). For 
fi ve of 15 subjects with COPD evaluated 
in this pilot analysis, both imaging and 
spirometry results suggested disease 
progression. This fi nding generates a 
number of hypotheses to test in larger 
or longer imaging studies of COPD pro-
gression that will evaluate the relation-
ship between exacerbations, treatment 
changes, and changes in quality of life 
with imaging and pulmonary function 
measurements. Future COPD studies 
that include hyperpolarized  3 He MR im-
aging will likely focus on a critical bal-
ance between longitudinal time frame 
in ex-smokers with COPD would be 
similar to those observed in healthy 
never-smokers, we observed an annu-
alized rate of change in  3 He MR imag-
ing–derived ADC of 0.01 cm 2 /sec—an 
order of magnitude greater than the 
rate previously reported (0.001 cm 2 /sec) 
for healthy nonsmokers in a cross-
sectional multicenter study at 1.5 T ( 29 ) 
and for the healthy never-smokers re-
ported in this study (0.002 cm 2 /sec). 
In addition, we observed no signifi cant 
change in  3 He MR imaging–derived 
ADC, ventilation defect measurements, 
or pulmonary function measurements 
for healthy never-smokers at follow-up. 
Fletcher and Peto ( 3 ), as well as the 
more recent fi ndings of a tiotropium in-
tervention trial ( 43 ), we were not sur-
prised to fi nd that in ex-smokers with 
COPD, FEV 1 did not signifi cantly change. 
Indeed, this study was not powered to 
detect such changes in FEV 1 during an 
approximately 2-year time frame; a ret-
rospective power analysis showed that 
a sample size of approximately 1000 
patients with COPD and 1000 healthy 
volunteers would be required to detect 
signifi cant change in FEV 1 in this study. 
Unlike the Fletcher curve prediction 
that longitudinal changes in hyperpo-
larized  3 He MR imaging measurements 
 Table 4 
 Relationship between FEV 1 Changes and  
3 He MR Imaging Measurement Changes for 
Subjects with COPD over the Course of Time 
Parameter FEV 
1
 (L) FEV 
1
 (Percentage Predicted) 
Whole-lung ADC (cm 2 /sec)  2 0.02 (.93) [.93] 0.17 (.56) [ . .99]
Center-section ADC (cm 2 /sec)  2 0.06 (.84) [ . .99] 0.15 (.60) [.60]
Whole-lung VDV (L)  2 0.56 (.03) [.09]  2 0.53 (.04) [.12]
Center-section VDV (L)  2 0.70 (.003) [.02]  2 0.67 (.007) [.04]
Whole-lung VDP (%)  2 0.60 (.02) [.08]  2 0.55 (.03) [.12]
Center-section VDP (%)  2 0.70 (.005) [.03]  2 0.70 (.005) [.03]
Note.—Data are Spearman correlation coeffi cients, with  P values in parentheses and Holm-Bonferroni–adjusted  P values in 
brackets.
 Figure 3 
  
 Figure 3: Scatterplots show the relationship 
between changes in FEV 
1
 and changes in  (a) 
center-section  (CS) VDP,  (b) center-section VDV, 
and  (c) whole-lung  (WL) ADC. Dotted lines = 95% 
confi dence intervals for the regressions. Changes 
in FEV 
1
 showed a signifi cant negative correlation 
with changes in center-section VDV ( r =  2 0.70, 
 P = .02) and center-section VDP ( r =  2 0.70, 
 P = .03). Changes in FEV 
1
 showed no signifi cant 
correlation with changes in whole-lung ADC. 
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established clinical measurements of 
COPD worsening. To make the impor-
tant conclusion that  3 He MR imaging 
measurements are specifi cally related to 
clinical measurements of COPD wors-
ening, future work in longer or larger 
studies must show that the detected 
 3 He MR imaging changes occurred in 
patients who had measureable clini-
cal changes. Nevertheless, the results 
suggest that  3 He MR imaging provides 
a sensitive method for the detection of 
structural and functional changes of the 
lung that accompany COPD longitudi-
nally. In the future, larger studies that 
directly compare  3 He MR imaging and 
other well-established clinical measure-
ments of COPD progression will be re-
quired to better understand the relation-
ship between  3 He MR imaging–derived 
measurements and other changes that 
occur in COPD over the course of time. 
In addition, a comparison of ex-smokers 
with COPD, healthy smokers, and cur-
rent smokers with COPD may help to 
establish and directly compare rates 
of structural and functional decline of 
the lung. It will also be critical to track 
patient exacerbations and changes in 
treatment during longer time periods to 
probe potential treatment effects with 
imaging. We also acknowledge that for 
this pilot study, we limited the COPD 
cohort to those with minimal FEV 1 re-
versibility, although clearly many sub-
jects with COPD have varying degrees 
of FEV 1 reversibility, which necessitates 
further work in such patients. 
 CT images were not prospectively 
acquired for this study; and therefore, 
our results cannot be directly compared 
with more-established CT measure-
ments such as percentage of low attenu-
ation areas (measurement of the extent 
of emphysema) or wall area percentage 
(measurement of airway wall thickness). 
Clearly, a direct comparison of CT 
and hyperpolarized  3 He MR imaging–
derived measurements in the same 
subjects will allow for a better under-
standing of differences in measurement 
sensitivity these imaging modalities 
provide. 
 A previous study ( 32 ) has shown sig-
nifi cant correlation between ADC and 
the measurement of diffusing capacity 
 Although this pilot study showed 
signifi cant increases in  3 He MR imaging–
derived measurements in just more 
than 2 years, we must acknowledge a 
number of specifi c limitations of our ap-
proach. We recognize that the relatively 
small group of subjects with COPD and 
healthy never-smokers who were evalu-
ated and the relatively short period of 
follow-up compared with other COPD 
longitudinal studies ( 5 ) certainly lim-
ited the applicability of our results. The 
small sample size necessitates cautious 
interpretation of the results, as well as 
the future requirement for larger stud-
ies to test the hypotheses generated. 
For example, because of the small num-
ber of healthy volunteers and subjects 
with COPD evaluated, signifi cant differ-
ences were not detected for pulmonary 
function measurements in either group. 
In addition, although we have previously 
demonstrated that ventilation defects 
are highly reproducible ( 20 ), the lack 
of longitudinal information regarding 
the variability of ventilation defects ne-
cessitates that the fi ndings of this study 
be interpreted with caution. 
 Although this pilot study showed 
that ex-smokers with COPD differed 
from never-smokers, it was not designed 
to show the relationship between the 
signifi cant imaging changes and more-
and fi nite numbers of subjects because 
of the relative complexity of these stud-
ies and the prediction for increased 
costs and decreased availability of  3 He 
gas for clinical research ( 44 ). Neverthe-
less, the preliminary fi ndings of this pi-
lot hyperpolarized  3 He MR imaging lon-
gitudinal study provide clear guidance 
for future COPD imaging studies on 
established and emerging imaging tools 
such as optical coherence tomography 
( 45 ), oxygen-enhanced and proton MR 
imaging methods ( 46,47 ), and hyperpo-
larized xenon 129 MR imaging. 
 Finally, we showed in an exploratory 
analysis, the potential relationship be-
tween smoking history and changes 
in  3 He MR imaging–derived VDV but 
not with changes in FEV 1 . Previous 
cross-sectional studies suggest ongo-
ing infl ammation in ex-smokers with 
COPD ( 3,29 ) and that smoking his-
tory correlated with current infl amma-
tory markers such as eosinophils ( 48 ) 
and vascular endothelial growth factor 
( 49 ), which supports the hypothesis 
that there is a predictive relationship 
between pack-years and infl ammation 
after smoking cessation. The results of 
this exploratory analysis of  3 He MR im-
aging changes and smoking history gen-
erate important hypotheses that future 
studies should explore in more detail. 
 Figure 4 
  
 Figure 4: Scatterplot shows the relationship between smoking history and change in whole-
lung  (WL) VDV ( r = 0.52;  P = .02;  P = .06, Holm-Bonferroni corrected) and change in FEV 
1
 
(percentage predicted) ( r = 0.05,  P = .83). 
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